受试者基本情况:核苷(酸)类似物治疗的29例慢乙肝患者(NA组:年龄49-66岁,ALT:16-28 U / L,HBsAg:93-1942 IU / mL)和41例无活动性肝炎的HBV携带者(无症状组:年龄:(44-65岁,ALT:16-29 U / L,HBsAg:267-3267 IU / mL)。
INDUCTION OF ANTI-HBS AND REDUCTION OF HBSAG BY NASAL ADMINISTRATION OF A THERAPEUTIC VACCINE CONTAINING HBSAG AND HBCAG (NASVAC) IN PATIENTS WITH CHRONIC HBV INFECTION